SCHEMBL31748342

SCHEMBL31748342

C[Si](C)(C)CCOCn1cc(C(=O)O)c2nc(Cl)c(F)cc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 1/20 0.41
▸ NFE2L2 Q16236 1/20 0.41
▸ KLKB1 P03952 1/20 0.37
▸ PTPN1 P18031 1/20 0.36
▸ DGAT1 O75907 6/20 0.35
▸ EGFR P00533 1/20 0.32
▸ IGF1R P08069 1/20 0.32
▸ SRC P12931 1/20 0.32
▸ FLT4 P35916 1/20 0.32
▸ KDR P35968 1/20 0.32
▸ FLT3 P36888 1/20 0.32
▸ EPHB4 P54760 1/20 0.32
▸ TEK Q02763 1/20 0.32
▸ NPC1 O15118 1/20 0.32
▸ CHRM1 P11229 1/20 0.32
▸ LMNA P02545 1/20 0.31
▸ CYP2C9 P11712 1/20 0.31
▸ ATP6V1B2 P21281 1/20 0.31
▸ TBXA2R P21731 1/20 0.31
▸ EDNRA P25101 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31748662 0.90 DGAT1 (0.38) KEAP1NFE2L2KLKB1PTPN1DGAT1
SCHEMBL31748492 0.89 DGAT1 (0.35) KEAP1NFE2L2KLKB1PTPN1DGAT1
SCHEMBL31748486 0.82 DGAT1 (0.33) PTPN1DGAT1EGFRIGF1RSRC
SCHEMBL31748668 0.80 DGAT1 (0.33) DGAT1EGFRIGF1RSRCFLT4
SCHEMBL31748388 0.77 KLKB1 (0.35) KLKB1PTPN1DGAT1EGFRIGF1R
SCHEMBL31748415 0.77 HDAC6 (0.33) KLKB1EGFRIGF1RSRCFLT4
SCHEMBL15569032 0.76 DGAT1 (0.37) KLKB1PTPN1DGAT1NPC1F11
SCHEMBL14738023 0.74 DGAT1 (0.42) KLKB1PTPN1DGAT1NPC1F11
SCHEMBL17548089 0.74 NPC1 (0.41) NPC1F11
SCHEMBL2564153 0.74 DGAT1 (0.37) KLKB1PTPN1DGAT1NPC1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF BIOLEXIS THERAPEUTICS INC (US) 2025-12-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250388571-A1 AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF PRKAB2, PRKAB1, PRKAR2B KEAP1 1186/4885NFE2L2 1538/4885KLKB1 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback